Swiss pharmaceutical firm Altamira Therapeutics Ltd (NASDAQ: CYTO) and its Chinese partner Nuance Pharma have announced an expansion of their licensing agreement for the anti-rhinitis spray Bentrio. The agreement extends the product’s reach to include Singapore, Malaysia, Thailand, the Philippines, Indonesia, Vietnam, and Taiwan, complementing the existing markets of China, Hong Kong, Macau, and South Korea.
Bentrio, a drug-free over-the-counter nasal spray, has been approved in the US, Europe, and other significant global markets. It forms a protective gel layer on the nasal mucosa, preventing the contact of viruses or allergens with cells and promoting the discharge and humidification of the nasal mucosa. Nuance has already secured approval for Bentrio in Hong Kong and is in the process of seeking approval in China.
The original partnership, initiated in 2022 with a USD 1 million upfront payment by Nuance, granted the company exclusive development and commercial rights to Bentrio. The expanded agreement is expected to broaden the product’s accessibility to over 630 million potential consumers in the region, offering relief to a significant patient population suffering from allergic rhinitis.- Flcube.com
